ArticleDiscover oncology2025
Identification and verification of exosome-related gene signature to predict the cancer status and prognosis of prostate cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Multifunctional Roles of Aquaporins in Tumors: Focusing on Metabolism, Migration, and Regulation of the Tumor Microenvironment.International journal of molecular sciences · 2026Review
- Molecular Cargo of Exosomes in Prostate Cancer: A Multi-Omics Perspective on Liquid Biopsies.Genes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundProstate cancer is one of the common malignant tumors in men. Recent studies have reported that non-invasive liquid biopsy is of great significance in tumor diagnosis. We hope to find relevant detection genes to establish a diagnostic and prognostic model for prostate cancer.
methodsThis study was based on the RNA expression data of prostate cancer patients from the The Cancer Genome Atlas (TCGA) database and the data of exosome-related genes from the GeneCards website. Key exosome-related differential genes were identified through cluster modeling, univariate and multivariate regression analyses. The roles of these genes in the occurrence and prognosis of prostate cancer were assessed using ROC curves and survival analysis. Validation was performed using prostate cancer patient data from the Gene Expression Omnibus (GEO) database.
resultsFirstly, we obtained 117 exosome-related differential genes (ERDEGs) from the RNA expression data of prostate cancer patients in the TCGA database. Next, through Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis, univariate Cox regression analysis, and multivariate Cox regression analysis of the ERDEGs, we obtained three genes that were significantly associated with prognosis (AQP2, H4C2, ZNF114) and calculated the risk score accordingly. Patients were divided into high-risk and low-risk groups based on this score, with significant differences in overall survival between the groups. At the same time, we conducted an immunological infiltration analysis on prostate cancer patients and Weighted correlation network analysis (WGCNA) on the ERDEGs. Finally, we used the GEO database (GSE69223, GSE229904) for verification and found that AQP2 and ZNF114 had good predictive value for the occurrence of prostate cancer.
conclusionExosome-related genes such as AQP2 and ZNF114 exhibit good performance as non-invasive biomarkers in predicting the status and prognosis of prostate cancer to avoid the issues of high invasiveness associated with invasive examinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.